$INBX (INHIBRX BIOSCIENCES) — 8-K: INBRX-106 plus pembrolizumab posts 48.3% cORR vs 26.5% in Phase 2 HNSCC

INBRX-106 plus pembrolizumab achieved a confirmed objective response rate of 48.3% compared with 26.5% for pembrolizumab alone in first-line PD-L1 positive HNSCC. Interim median PFS was 9.6 months versus 4.9 months, with six-month PFS rates of 72.4% versus 42.8%. In HPV+ patients, cORR was 80.0% versus 33.3%, complete response rate was 30.0% versus 0%, and six-month PFS was 90.0% versus 33.0%. Inhibrx will expand the Phase 2 study by approximately 50 HPV+ patients, which may support a pathway to accelerated approval.

INBRX-106 plus pembrolizumab achieved a confirmed objective response rate of 48.3% compared with 26.5% for pembrolizumab alone in first-line PD-L1 positive HNSCC. Interim median PFS was 9.6 months ver